Polymorphs of azabicyclohexane
The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.
1. A method for the treatment of depression in a patient in need of said treatment comprising administering to said patient an effective amount of polymorph form A of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane hydrochloride substantially free of other geometric and optical isomers and polymorphic forms thereof.
2. The method of claim 1 wherein said polymorph form A is administered to the patient at an oral dose of from about 0.5 mg/kg to about 5.0 mg/kg of body weight per day.
3. The method of claim 1 wherein said polymorph form A is administered to the patient by oral, buccal, nasal, pulmonary, aerosol, topical, transdermal, mucosal, or injectable delivery.
4. The method of claim 1 wherein said polymorph form A is administered to the patient at an oral dose of from about 30 mg to 300 mg per day.
5. The method of claim 1 wherein said polymorph form A is administered to the patient at an oral dose of from about 50 mg to 200 mg per day.
6. The method of claim 1 wherein said polymorph form A is administered to the patient at a unit dosage of from about 100 mg to 800 mg.
7. The method of claim 1 wherein said polymorph form A is administered to the patient at a dosage of from about 100 mg to 200 mg.
8. The method of claim 1 wherein said polymorph form A is administered to the patient at a dosage of from about 250 mg to 500 mg.
9. The method of claim 1 wherein said polymorph form A is administered to the patient at a dose of from about 1 mg/kg to about 15 mg/kg of body weight per day.
10. The method of claim 9 wherein said polymorph form A is administered to the patient at a dose of from about 1 mg/kg to about 10 mg/kg of body weight per day.
11. The method of claim 1 wherein said polymorph form A is administered to the patient at a unit dosage of from about 50 mg to 1000 mg.
12. The method of claim 1 wherein said polymorph form A is administered to the patient at a unit dosage of from about 150 mg to 600 mg.
13. The method of claim 3 wherein said polymorph form A is administered to the patient by oral delivery.